Latrodectus antivenin

Drug Profile

Latrodectus antivenin

Alternative Names: Analatro; Antivenin Latrodectus equine immune F(ab)2 - RDT/Bioclon; Aracmyn; Black widow spider antivenin - RDT/Bioclon; Black widow spider antivenom - RDT/Bioclon; Latrodectus immune F(ab’)2 antivenom - Instituto Bioclon/Rare disease therapeutics; Spider venom antiserum - RDT/Bioclon

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antibodies; Antivenins
  • Mechanism of Action Spider venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spider venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spider venom poisoning

Most Recent Events

  • 12 Aug 2005 Phase-II clinical trials in Spider venom poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top